There is currently no confirmed causal link between retatrutide and joint pain, as the drug remains unlicensed and Phase 3 trial data are still being collected
As of 2026, retatrutide has not been approved by the MHRA, FDA, EMA, or any other regulatory authority for human or veterinary use
The potential role of GLP-1 agonists in treating alcohol use disorder (AUD) has emerged from both animal studies and early-phase human trials, though it is important to emphasise that there is no official licence for these medications in AUD treatment in the UK or elsewhere
(Lausanne) 13 , 863184 (2022)
CareClinics injection tracker ensures you never miss a dose, forget an injection site, or lose track of your dosing timeline, giving you peace of mind week after week
Retatrutide adds a third: glucagon, which sounds counterintuitive but in chronic activation raises energy expenditure and pulls fat out of the liver